<DOC>
	<DOC>NCT00813605</DOC>
	<brief_summary>This is a phase 2, multicenter, randomized, double-blind, double-dummy, placebo-controlled, three-arm trial to be conducted in the United States, Europe, and Asia. Approximately 150 eligible KRAS-mutant metastatic colorectal cancer subjects who have failed first line fluoropyrimidine and oxaliplatin-based regimen with or without anti-VEGF therapy will be randomized in a 1:1:1 ratio to receive AMG 479 placebo plus AMG 655 with FOLFIRI, or AMG 479 plus AMG 655 placebo with FOLFIRI, or AMG 479 placebo plus AMG 655 placebo with FOLFIRI</brief_summary>
	<brief_title>QUILT-2.018: Safety &amp; Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of colon or rectum in patients with metastatic disease Mutanttype KRAS tumor at screening Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1 Adequate hematology, renal, hepatic, and coagulation function History or known presence of central nervous system metastases History of other malignancy Prior irinotecanbased chemotherapy for advanced/metastatic disease Prior death receptor agonists, or other systemic IGF1R agonists in any setting Uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>AMG 655</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>metastatic cancer</keyword>
	<keyword>antibody-2nd line</keyword>
	<keyword>KRAS</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>